Great news out this morning on NASDAQ:AKER, "Akers Biosciences Inc. has entered into a three-year national distribution agreement for its flagship product with Diagnostica Stago Inc. Under the three-year deal, Stago will distribute South Jersey-based Akers PIFA PLUSS PF4 Rapid Assay, a single-use test for Heparin-induced thrombocytopenia to its customer base of hospital laboratories across the United States." (Source: John George – Senior Reporter, Philadelphia Business Journal)
This news caused the morning spike hitting a HOD of $0.9803 and closing strong at $0.92 (+15.43%) completely jumping over that trend line . With FDA still around the corner regarding their PIFA Chlamydia™ and ER expected to release on Thursday 3/29/18, we should see a very good future ahead! Next resistance may be around $1.08 but with great ER it should be able to break that, with FDA we'll be flying past $1.50 in my opinion.
Recommendation: Buy/Hold
This news caused the morning spike hitting a HOD of $0.9803 and closing strong at $0.92 (+15.43%) completely jumping over that trend line . With FDA still around the corner regarding their PIFA Chlamydia™ and ER expected to release on Thursday 3/29/18, we should see a very good future ahead! Next resistance may be around $1.08 but with great ER it should be able to break that, with FDA we'll be flying past $1.50 in my opinion.
Recommendation: Buy/Hold